ClinicalTrials.gg
CompletedNCT05565742Updated May 28, 2025Results posted

A Study of LY3819469 in Participants With Elevated Lipoprotein(a) [Lp(a)]

A Phase 2 interventional study of LY3819469 and Placebo in Lipoprotein Disorder, sponsored by Eli Lilly and Company. Completed at 80 sites in 10 countries. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2025-05-28.

Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
320
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Study summary

The main purpose of this study is to determine the efficacy and safety of LY3819469 in adults with elevated lipoprotein(a). The study will lasts about 20 months.

02

Conditions studied

  • Lipoprotein Disorder
03

In context

Lead sponsor

Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.

Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must be at least 40 years old at the time of signing the .
  • Participants with Lp(a) ≥175 nmol/L at screening, measured at the central laboratory
  • Participants on the following medications according to local practice must be on a stable regimen for at least 4 weeks prior to screening and randomization and expected to remain on a stable regimen through the end of the Treatment and Assessment Period:

    • lipid-lowering drugs
    • testosterone, estrogens, anti-estrogens, progestins, selective estrogen receptor modulators, or growth hormone
    • Have a within the range 18.5 to 40 kilogram/square meter (kg/m²), inclusive.

Male and/or Female

  • Males who agree to use highly effective/effective methods of may participate in this trial.
  • Women not of (WNOCBP) may participate in this trial.

Exclusion criteria

Exclusion Criteria:

  • Have a history or presence of an underlying disease, or surgical, physical, medical, or psychiatric condition that, in the opinion of the investigator, would potentially affect participant safety within the study or interfere with participating in or completing the study or with the interpretation of data.
  • Any of the following, or other events indicating unstable medical condition in the opinion of the investigator, within 3 months of randomization:

    • major surgery
    • coronary, carotid, or peripheral arterial revascularization
    • stroke or
    • myocardial infarction or unstable angina
    • acute limb ischemia
  • Have, in the 6 months prior to day 1, uncontrolled Type 1 or Type 2 diabetes.
  • Have uncontrolled hypertension
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
320 participants (actual)

Study arms

  • Experimental
    16 mg LY3819469

    Participants received 16 milligrams (mg) of LY3819469 on day 1 and day 180, administered as a subcutaneous (SC) injection.

    Drug: LY3819469

  • Experimental
    96 mg LY3819469

    Participants received 96 mg of LY3819469 on day 1 and day 180, administered as a SC injection.

    Drug: LY3819469

  • Experimental
    400 mg LY3819469

    Participants received 400 mg of LY3819469 on day 1 and day 180, administered as a SC injection.

    Drug: LY3819469

  • Experimental
    400 mg LY3819469 + Placebo

    Participants received 400 mg of LY3819469 on day 1 and placebo on day 180, administered as a SC injection.

    Drug: LY3819469 · Drug: Placebo

  • Placebo comparator
    Placebo

    Participants received placebo on day 1 and day 180, administered as a SC injection.

    Drug: Placebo

Interventions

  • Administered SC

  • DrugPlacebo

    Administered SC

06

What researchers measure

Primary outcomes

  1. Percent Change From Baseline in Time Averaged Lipoprotein(a) [Lp(a)] Over Days 60-180

    LPa levels were assessed using Immuno turbidimetric method. Percent change is calculated as: Percent Change=\[(Lp(a) at Time Point-Lp(a) at Baseline)/Lp(a) at Baseline\]×100 Least squares (LS) mean was determined using mixed model repeated measures (MMRM) model with log(Lp(a)) - log(Baseline) = log(Baseline) + Treatment + Time + Treatment\*Time (Type III sum of squares) as post-baseline measures. Result presented is after back-transformation. Variance-Covariance structure = Unstructured. Analyses included all participants having non-missing baseline and at least one non-missing post-baseline value of the response variable.

    Time frame: Baseline, Days 60 - 180

Secondary outcomes

  1. Percent Change From Baseline in Time Averaged Lp(a) Over Days 240-360

    LPa levels were assessed using Immuno turbidimetric method. LS mean was determined using MMRM model with log(Lp(a)) - log(Baseline) = log(Baseline) + Treatment + Time + Treatment\*Time (Type III sum of squares) as post-baseline measures.. Result presented is after back-transformation. Variance-Covariance structure = Unstructured. Analyses included all participants having non-missing baseline and at least one non-missing post-baseline value of the response variable.

    Time frame: Baseline, Days 240 - 360

  2. Percentage of Participants Achieving Lp(a) <125 and <75 Nanomole/Liter (Nmol/L) at Days 60, 180

    Percentage of Participants Achieving Lp(a) \<125 and \<75 Nanomole/Liter (nmol/L) at Days 60, 180 is reported.

    Time frame: Days 60, 180

  3. Percentage of Participants Achieving Lp(a) <125 and <75 Nanomole/Liter (Nmol/L) at Days 240, 360, and 540

    Percentage of Participants Achieving Lp(a) \<125 and \<75 Nanomole/Liter (Nmol/L) at Days 240, 360, and 540 is reported.

    Time frame: Days 240, 360, and 540

  4. Percent Change From Baseline in Lp(a)

    LS mean was determined using MMRM model with log(Actual Measurement/Baseline) = log (Baseline) + High Risk CV Stratum (yes/no) + Treatment + Time + Treatment\*Time (Type III sum of squares) as post-baseline measures. Variance-Covariance structure (Change from Baseline) = Unstructured. Analyses included all participants having non-missing baseline and at least one non-missing post-baseline value of the response variable.

    Time frame: Baseline, Days 60, 180, 240, 360, and 540

  5. Percent Change From Baseline in Apolipoprotein B (ApoB)

    LS mean was determined using MMRM model with log (Actual Measurement/Baseline) = log(Baseline) + Baseline Lp(a) stratum (\<275 nmol/L vs. \>=275 nmol/L) + High Risk CV Stratum (yes/no) + Treatment + Time + Treatment\*Time (Type III sum of squares as post-baseline measures. Variance-Covariance structure (Change from Baseline) = Unstructured. Analyses included all participants having non-missing baseline and at least one non-missing post-baseline value of the response variable.

    Time frame: Baseline, Days 60, 180, 240, 360, and 540

  6. Percent Change From Baseline in High-sensitivity C-reactive Protein (hsCRP)

    hsCRP is a laboratory analyte that is an indicator of inflammation. Decreases in hsCRP represent reductions in inflammation. LS mean was determined using MMRM model with log (Actual Measurement/Baseline) = log(Baseline) + Baseline Lp(a) stratum (\<275 nmol/L vs. \>=275 nmol/L) + High Risk CV Stratum (yes/no) + Treatment + Time + Treatment\*Time (Type III sum of squares as post-baseline measures. Variance-Covariance structure (Change from Baseline) = Unstructured. Analyses included all participants having non-missing baseline and at least one non-missing post-baseline value of the response variable.

    Time frame: Baseline, Days 60, 180, 240, 360, and 540

  7. Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC[0-inf]) of LY3819469

    AUC was computed using the population PK model. Therefore, the concentrations are simulated from time 0 to infinity to estimate AUC for each participant. The timeframe reflects the PK timepoints that were collected to develop the population PK. Although this is a multiple dose study, the plasma PK is very short, so AUC0-180days is equivalent to AUC0-infinity.

    Time frame: Day 1: 0.5 hours, 4-9 hours post-dose; Day 180: 24-36 hours post-dose

07

Results

Posted May 28, 2025

Participant flow

Participant flow — Overall Study
Milestone16 mg LY381946996 mg LY3819469400 mg LY3819469400 mg LY3819469 + PlaceboPlacebo
Started3674697269
Received at least one dose of study drug3674697269
Full analysis set (fas)3674697269
Efficacy analysis set (eas)3674697269
Completed3574677066
Not completed10223
Withdrew: Withdrawal by subject00222
Withdrew: Death10000
Withdrew: Participant travelled abroad00001

Outcome measures

PrimaryPercent Change From Baseline in Time Averaged Lipoprotein(a) [Lp(a)] Over Days 60-180

LPa levels were assessed using Immuno turbidimetric method. Percent change is calculated as: Percent Change=\[(Lp(a) at Time Point-Lp(a) at Baseline)/Lp(a) at Baseline\]×100 Least squares (LS) mean was determined using mixed model repeated measures (MMRM) model with log(Lp(a)) - log(Baseline) = log(Baseline) + Treatment + Time + Treatment\*Time (Type III sum of squares) as post-baseline measures. Result presented is after back-transformation. Variance-Covariance structure = Unstructured. Analyses included all participants having non-missing baseline and at least one non-missing post-baseline value of the response variable.

Time frame:
Baseline, Days 60 - 180
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Time Averaged Lipoprotein(a) [Lp(a)] Over Days 60-180
percent change16 mg LY381946996 mg LY3819469400 mg LY3819469 and 400 mg LY3819469 + Placebo (400 mg LY3819469 Pooled)Placebo
Percent Change From Baseline in Time Averaged Lipoprotein(a) [Lp(a)] Over Days 60-180-39.0 ± 7.37-74.4 ± 2.16-93.7 ± 0.383.1 ± 8.99
Statistical analysis
  • 16 mg LY3819469 vs Placebo · Mixed Models Analysis · p = <0.001 · Ls mean difference (final values): -40.8 · 95% CI -55.8 to -20.6
  • 96 mg LY3819469 vs Placebo · Mixed Models Analysis · p = <0.001 · Ls mean difference (final values): -75.2 · 95% CI -80.4 to -68.5
  • 400 mg LY3819469 and 400 mg LY3819469 + Placebo (400 mg LY3819469 Pooled) vs Placebo · Mixed Models Analysis · p = <0.001 · Ls mean difference (final values): -93.9 · 95% CI -95.1 to -92.5
SecondaryPercent Change From Baseline in Time Averaged Lp(a) Over Days 240-360

LPa levels were assessed using Immuno turbidimetric method. LS mean was determined using MMRM model with log(Lp(a)) - log(Baseline) = log(Baseline) + Treatment + Time + Treatment\*Time (Type III sum of squares) as post-baseline measures.. Result presented is after back-transformation. Variance-Covariance structure = Unstructured. Analyses included all participants having non-missing baseline and at least one non-missing post-baseline value of the response variable.

Time frame:
Baseline, Days 240 - 360
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Time Averaged Lp(a) Over Days 240-360
percent change16 mg LY381946996 mg LY3819469400 mg LY3819469400 mg LY3819469 + PlaceboPlacebo
Percent Change From Baseline in Time Averaged Lp(a) Over Days 240-360-38.7 ± 7.66-77.4 ± 1.97-95.0 ± 0.45-76.7 ± 2.060.3 ± 9.07
Statistical analysis
  • 16 mg LY3819469 vs Placebo · Mixed Models Analysis · p = 0.002 · Ls mean difference (final values): -38.9 · 95% CI -54.9 to -17.2
  • 96 mg LY3819469 vs Placebo · Mixed Models Analysis · p = <0.001 · Ls mean difference (final values): -77.4 · 95% CI -82.4 to -71.1
  • 400 mg LY3819469 vs Placebo · Mixed Models Analysis · p = <0.001 · Ls mean difference (final values): -95.0 · 95% CI -96.1 to -93.6
  • 400 mg LY3819469 + Placebo vs Placebo · Mixed Models Analysis · p = <0.001 · Ls mean difference (final values): -76.8 · 95% CI -81.9 to -70.2
SecondaryPercentage of Participants Achieving Lp(a) <125 and <75 Nanomole/Liter (Nmol/L) at Days 60, 180

Percentage of Participants Achieving Lp(a) \<125 and \<75 Nanomole/Liter (nmol/L) at Days 60, 180 is reported.

Time frame:
Days 60, 180
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Lp(a) <125 and <75 Nanomole/Liter (Nmol/L) at Days 60, 180
percentage of participants16 mg LY381946996 mg LY3819469400 mg LY3819469 and 400 mg LY3819469 + Placebo (400 mg LY3819469 Pooled)Placebo
Lp(a) <125 nmol/L: Day 6037.1486.3097.810.00
Lp(a) <125 nmol/L: Day 18014.2958.3390.150.00
Lp(a) <75 nmol/L: Day 6014.2964.3896.350.00
Lp(a) <75 nmol/L: Day 1808.5733.3381.060.00
Statistical analysis
  • 16 mg LY3819469 vs Placebo · Regression, Logistic · p = 0.001 · Odds ratio (or): 112.03 · 95% CI 6.35 to 1975.13
  • 96 mg LY3819469 vs Placebo · Regression, Logistic · p = <0.001 · Odds ratio (or): 2762.52 · 95% CI 142.74 to 53463.34
  • 400 mg LY3819469 and 400 mg LY3819469 + Placebo (400 mg LY3819469 Pooled) vs Placebo · Regression, Logistic · p = <0.001 · Odds ratio (or): 50904.09 · 95% CI 1700.95 to 1523398.10
  • 16 mg LY3819469 vs Placebo · Regression, Logistic · p = 0.026 · Odds ratio (or): 27.94 · 95% CI 1.48 to 527.74
  • 96 mg LY3819469 vs Placebo · Regression, Logistic · p = <0.001 · Odds ratio (or): 309.36 · 95% CI 17.99 to 5320.81
  • 400 mg LY3819469 and 400 mg LY3819469 + Placebo (400 mg LY3819469 Pooled) vs Placebo · Regression, Logistic · p = <0.001 · Odds ratio (or): 3060.16 · 95% CI 166.84 to 56127.55
  • 16 mg LY3819469 vs Placebo · Regression, Logistic · p = 0.021 · Odds ratio (or): 32.91 · 95% CI 1.70 to 635.94
  • 96 mg LY3819469 vs Placebo · Regression, Logistic · p = <0.001 · Odds ratio (or): 579.62 · 95% CI 31.48 to 10673.41
  • 400 mg LY3819469 and 400 mg LY3819469 + Placebo (400 mg LY3819469 Pooled) vs Placebo · Regression, Logistic · p = <0.001 · Odds ratio (or): 14659.81 · 95% CI 646.35 to 332498.98
  • 16 mg LY3819469 vs Placebo · Regression, Logistic · p = 0.071 · Odds ratio (or): 15.94 · 95% CI 0.79 to 321.21
  • 96 mg LY3819469 vs Placebo · Regression, Logistic · p = 0.002 · Odds ratio (or): 86.32 · 95% CI 5.07 to 1468.36
  • 400 mg LY3819469 and 400 mg LY3819469 + Placebo (400 mg LY3819469 Pooled) vs Placebo · Regression, Logistic · p = <0.001 · Odds ratio (or): 956.84 · 95% CI 55.75 to 16422.76
SecondaryPercentage of Participants Achieving Lp(a) <125 and <75 Nanomole/Liter (Nmol/L) at Days 240, 360, and 540

Percentage of Participants Achieving Lp(a) \<125 and \<75 Nanomole/Liter (Nmol/L) at Days 240, 360, and 540 is reported.

Time frame:
Days 240, 360, and 540
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Lp(a) <125 and <75 Nanomole/Liter (Nmol/L) at Days 240, 360, and 540
percentage of participants16 mg LY381946996 mg LY3819469400 mg LY3819469400 mg LY3819469 + PlaceboPlacebo
Lp(a) <125 nmol/L: Day 24036.3688.0698.4178.791.56
Lp(a) <125 nmol/L: Day 36024.2458.8288.8959.380.00
Lp(a) <125 nmol/L: Day 5409.3832.3175.4135.480.00
Lp(a) <75 nmol/L: Day 24018.1876.1296.8365.151.56
Lp(a) <75 nmol/L: Day 3606.0641.1882.5442.190.00
Lp(a) <75 nmol/L: Day 5400.0016.9245.9016.130.00
Statistical analysis
  • 16 mg LY3819469 vs Placebo · Regression, Logistic · p = <0.001 · Odds ratio (or): 32.05 · 95% CI 5.36 to 191.58
  • 96 mg LY3819469 vs Placebo · Regression, Logistic · p = <0.001 · Odds ratio (or): 602.39 · 95% CI 95.36 to 3805.22
  • 400 mg LY3819469 vs Placebo · Regression, Logistic · p = <0.001 · Odds ratio (or): 6953.37 · 95% CI 527.56 to 91646.24
  • 400 mg LY3819469 + Placebo vs Placebo · Regression, Logistic · p = <0.001 · Odds ratio (or): 347.76 · 95% CI 57.46 to 2104.62
  • 16 mg LY3819469 vs Placebo · Regression, Logistic · p = 0.007 · Odds ratio (or): 54.99 · 95% CI 2.98 to 1015.84
  • 96 mg LY3819469 vs Placebo · Regression, Logistic · p = <0.001 · Odds ratio (or): 363.15 · 95% CI 20.83 to 6332.68
  • 400 mg LY3819469 vs Placebo · Regression, Logistic · p = <0.001 · Odds ratio (or): 2953.53 · 95% CI 150.95 to 57790.71
  • 400 mg LY3819469 + Placebo vs Placebo · Regression, Logistic · p = <0.001 · Odds ratio (or): 375.16 · 95% CI 21.46 to 6571.66
  • 16 mg LY3819469 vs Placebo · Regression, Logistic · p = 0.068 · Odds ratio (or): 16.43 · 95% CI 0.81 to 331.69
  • 96 mg LY3819469 vs Placebo · Regression, Logistic · p = 0.002 · Odds ratio (or): 84.97 · 95% CI 4.99 to 1447.48
  • 400 mg LY3819469 vs Placebo · Regression, Logistic · p = <0.001 · Odds ratio (or): 594.66 · 95% CI 33.99 to 10405.09
  • 400 mg LY3819469 + Placebo vs Placebo · Regression, Logistic · p = 0.001 · Odds ratio (or): 110.17 · 95% CI 6.47 to 1875.77
  • 16 mg LY3819469 vs Placebo · Regression, Logistic · p = 0.010 · Odds ratio (or): 11.61 · 95% CI 1.81 to 74.29
  • 96 mg LY3819469 vs Placebo · Regression, Logistic · p = <0.001 · Odds ratio (or): 233.25 · 95% CI 39.92 to 1362.79
  • 400 mg LY3819469 vs Placebo · Regression, Logistic · p = <0.001 · Odds ratio (or): 3087.58 · 95% CI 331.26 to 28778.10
  • 400 mg LY3819469 + Placebo vs Placebo · Regression, Logistic · p = <0.001 · Odds ratio (or): 144.58 · 95% CI 25.20 to 829.42
  • 16 mg LY3819469 vs Placebo · Regression, Logistic · p = 0.125 · Odds ratio (or): 11.16 · 95% CI 0.51 to 243.85
  • 96 mg LY3819469 vs Placebo · Regression, Logistic · p = <0.001 · Odds ratio (or): 148.30 · 95% CI 8.64 to 2546.89
  • 400 mg LY3819469 vs Placebo · Regression, Logistic · p = <0.001 · Odds ratio (or): 1431.38 · 95% CI 77.76 to 26349.86
  • 400 mg LY3819469 + Placebo vs Placebo · Regression, Logistic · p = <0.001 · Odds ratio (or): 147.78 · 95% CI 8.60 to 2538.95
  • 16 mg LY3819469 vs Placebo · Regression, Logistic · p = 0.733 · Odds ratio (or): 1.99 · 95% CI 0.04 to 104.02
  • 96 mg LY3819469 vs Placebo · Regression, Logistic · p = 0.015 · Odds ratio (or): 34.28 · 95% CI 1.98 to 594.46
  • 400 mg LY3819469 vs Placebo · Regression, Logistic · p = <0.001 · Odds ratio (or): 159.77 · 95% CI 9.40 to 2716.42
  • 400 mg LY3819469 + Placebo vs Placebo · Regression, Logistic · p = 0.013 · Odds ratio (or): 37.98 · 95% CI 2.19 to 659.75
SecondaryPercent Change From Baseline in Lp(a)

LS mean was determined using MMRM model with log(Actual Measurement/Baseline) = log (Baseline) + High Risk CV Stratum (yes/no) + Treatment + Time + Treatment\*Time (Type III sum of squares) as post-baseline measures. Variance-Covariance structure (Change from Baseline) = Unstructured. Analyses included all participants having non-missing baseline and at least one non-missing post-baseline value of the response variable.

Time frame:
Baseline, Days 60, 180, 240, 360, and 540
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Lp(a)
percent change16 mg LY381946996 mg LY3819469400 mg LY3819469400 mg LY3819469 + PlaceboPlacebo
Baseline, Day 60-46.2 ± 6.04-80.4 ± 1.53-95.4 ± 0.26-95.4 ± 0.262.2 ± 8.29
Baseline, Day 180-30.5 ± 9.17-65.3 ± 3.20-90.5 ± 0.64-90.5 ± 0.642.2 ± 9.78
Baseline, Day 240-47.7 ± 6.63-84.8 ± 1.35-96.8 ± 0.23-84.9 ± 1.09-0.8 ± 9.10
Baseline, Day 360-30.8 ± 9.19-67.7 ± 2.99-91.1 ± 0.69-68.1 ± 2.46-0.9 ± 9.53
Baseline, Day 540-18.7 ± 8.56-45.1 ± 4.04-73.8 ± 1.69-52.8 ± 3.041.3 ± 7.76
Statistical analysis
  • 16 mg LY3819469 vs Placebo · Mixed Models Analysis · p = <0.001 · Ls mean difference (final values): -47.4 · 95% CI -59.9 to -30.9
  • 96 mg LY3819469 vs Placebo · Mixed Models Analysis · p = <0.001 · Ls mean difference (final values): -80.9 · 95% CI -84.7 to -76.1
  • 400 mg LY3819469 vs Placebo · Mixed Models Analysis · p = <0.001 · Ls mean difference (final values): -95.5 · 95% CI -96.3 to -94.5
  • 400 mg LY3819469 + Placebo vs Placebo · Mixed Models Analysis · p = <0.001 · Ls mean difference (final values): -95.5 · 95% CI -96.3 to -94.5
  • 16 mg LY3819469 vs Placebo · Mixed Models Analysis · p = 0.019 · Ls mean difference (final values): -31.9 · 95% CI -50.6 to -6.2
  • 96 mg LY3819469 vs Placebo · Mixed Models Analysis · p = <0.001 · Ls mean difference (final values): -66.0 · 95% CI -73.8 to -55.9
  • 400 mg LY3819469 vs Placebo · Mixed Models Analysis · p = <0.001 · Ls mean difference (final values): -90.7 · 95% CI -92.6 to -88.3
  • 400 mg LY3819469 + Placebo vs Placebo · Mixed Models Analysis · p = <0.001 · Ls mean difference (final values): -90.7 · 95% CI -92.6 to -88.3
  • 16 mg LY3819469 vs Placebo · Mixed Models Analysis · p = <0.001 · Ls mean difference (final values): -47.3 · 95% CI -61.3 to -28.3
  • 96 mg LY3819469 vs Placebo · Mixed Models Analysis · p = <0.001 · Ls mean difference (final values): -84.7 · 95% CI -88.1 to -80.3
  • 400 mg LY3819469 vs Placebo · Mixed Models Analysis · p = <0.001 · Ls mean difference (final values): -96.8 · 95% CI -97.4 to -95.9
  • 400 mg LY3819469 + Placebo vs Placebo · Mixed Models Analysis · p = <0.001 · Ls mean difference (final values): -84.7 · 95% CI -87.9 to -80.8
  • 16 mg LY3819469 vs Placebo · Mixed Models Analysis · p = 0.029 · Ls mean difference (final values): -30.2 · 95% CI -49.4 to -3.6
  • 96 mg LY3819469 vs Placebo · Mixed Models Analysis · p = <0.001 · Ls mean difference (final values): -67.4 · 95% CI -74.9 to -57.6
  • 400 mg LY3819469 vs Placebo · Mixed Models Analysis · p = <0.001 · Ls mean difference (final values): -91.0 · 95% CI -92.9 to -88.5
  • 400 mg LY3819469 + Placebo vs Placebo · Mixed Models Analysis · p = <0.001 · Ls mean difference (final values): -67.8 · 95% CI -74.8 to -59.0
  • 16 mg LY3819469 vs Placebo · Mixed Models Analysis · p = 0.093 · Ls mean difference (final values): -19.7 · 95% CI -37.8 to 3.7
  • 96 mg LY3819469 vs Placebo · Mixed Models Analysis · p = <0.001 · Ls mean difference (final values): -45.8 · 95% CI -56.0 to -33.2
  • 400 mg LY3819469 vs Placebo · Mixed Models Analysis · p = <0.001 · Ls mean difference (final values): -74.2 · 95% CI -78.8 to -68.5
  • 400 mg LY3819469 + Placebo vs Placebo · Mixed Models Analysis · p = <0.001 · Ls mean difference (final values): -53.4 · 95% CI -61.7 to -43.3
SecondaryPercent Change From Baseline in Apolipoprotein B (ApoB)

LS mean was determined using MMRM model with log (Actual Measurement/Baseline) = log(Baseline) + Baseline Lp(a) stratum (\<275 nmol/L vs. \>=275 nmol/L) + High Risk CV Stratum (yes/no) + Treatment + Time + Treatment\*Time (Type III sum of squares as post-baseline measures. Variance-Covariance structure (Change from Baseline) = Unstructured. Analyses included all participants having non-missing baseline and at least one non-missing post-baseline value of the response variable.

Time frame:
Baseline, Days 60, 180, 240, 360, and 540
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Apolipoprotein B (ApoB)
percent change16 mg LY381946996 mg LY3819469400 mg LY3819469400 mg LY3819469 + PlaceboPlacebo
Baseline, Day 60-10.2 ± 3.07-11.8 ± 2.10-13.9 ± 1.49-13.9 ± 1.490.2 ± 2.47
Baseline, Day 180-7.0 ± 3.49-9.6 ± 2.37-12.6 ± 1.68-12.6 ± 1.681.3 ± 2.78
Baseline, Day 240-7.6 ± 3.24-13.8 ± 2.11-14.0 ± 1.98-9.0 ± 2.051.8 ± 2.58
Baseline, Day 360-2.9 ± 3.56-8.1 ± 2.35-10.4 ± 2.20-4.6 ± 2.334.3 ± 2.77
Baseline, Day 5401.4 ± 3.55-0.6 ± 2.42-9.1 ± 2.13-0.9 ± 2.314.3 ± 2.64
Statistical analysis
  • 16 mg LY3819469 vs Placebo · Mixed Models Analysis · p = 0.010 · Ls mean difference (final values): -10.4 · 95% CI -17.5 to -2.6
  • 96 mg LY3819469 vs Placebo · Mixed Models Analysis · p = <0.001 · Ls mean difference (final values): -11.9 · 95% CI -17.7 to -5.8
  • 400 mg LY3819469 vs Placebo · Mixed Models Analysis · p = <0.001 · Ls mean difference (final values): -14.1 · 95% CI -19.0 to -8.8
  • 400 mg LY3819469 + Placebo vs Placebo · Mixed Models Analysis · p = <0.001 · Ls mean difference (final values): -14.1 · 95% CI -19.0 to -8.8
  • 16 mg LY3819469 vs Placebo · Mixed Models Analysis · p = 0.068 · Ls mean difference (final values): -8.2 · 95% CI -16.2 to 0.6
  • 96 mg LY3819469 vs Placebo · Mixed Models Analysis · p = 0.003 · Ls mean difference (final values): -10.7 · 95% CI -17.1 to -3.8
  • 400 mg LY3819469 vs Placebo · Mixed Models Analysis · p = <0.001 · Ls mean difference (final values): -13.7 · 95% CI -19.3 to -7.9
  • 400 mg LY3819469 + Placebo vs Placebo · Mixed Models Analysis · p = <0.001 · Ls mean difference (final values): -13.7 · 95% CI -19.3 to -7.9
  • 16 mg LY3819469 vs Placebo · Mixed Models Analysis · p = 0.026 · Ls mean difference (final values): -9.2 · 95% CI -16.7 to -1.2
  • 96 mg LY3819469 vs Placebo · Mixed Models Analysis · p = <0.001 · Ls mean difference (final values): -15.4 · 95% CI -21.1 to -9.3
  • 400 mg LY3819469 vs Placebo · Mixed Models Analysis · p = <0.001 · Ls mean difference (final values): -15.5 · 95% CI -21.0 to -9.6
  • 400 mg LY3819469 + Placebo vs Placebo · Mixed Models Analysis · p = <0.001 · Ls mean difference (final values): -10.6 · 95% CI -16.3 to -4.4
  • 16 mg LY3819469 vs Placebo · Mixed Models Analysis · p = 0.111 · Ls mean difference (final values): -7.0 · 95% CI -14.9 to 1.7
  • 96 mg LY3819469 vs Placebo · Mixed Models Analysis · p = <0.001 · Ls mean difference (final values): -12.0 · 95% CI -18.1 to -5.3
  • 400 mg LY3819469 vs Placebo · Mixed Models Analysis · p = <0.001 · Ls mean difference (final values): -14.1 · 95% CI -20.0 to -7.8
  • 400 mg LY3819469 + Placebo vs Placebo · Mixed Models Analysis · p = 0.013 · Ls mean difference (final values): -8.6 · 95% CI -14.9 to -1.9
  • 16 mg LY3819469 vs Placebo · Mixed Models Analysis · p = 0.510 · Ls mean difference (final values): -2.8 · 95% CI -10.7 to 5.8
  • 96 mg LY3819469 vs Placebo · Mixed Models Analysis · p = 0.173 · Ls mean difference (final values): -4.7 · 95% CI -11.1 to 2.1
  • 400 mg LY3819469 vs Placebo · Mixed Models Analysis · p = <0.001 · Ls mean difference (final values): -12.9 · 95% CI -18.6 to -6.8
  • 400 mg LY3819469 + Placebo vs Placebo · Mixed Models Analysis · p = 0.139 · Ls mean difference (final values): -5.0 · 95% CI -11.2 to 1.7
SecondaryPercent Change From Baseline in High-sensitivity C-reactive Protein (hsCRP)

hsCRP is a laboratory analyte that is an indicator of inflammation. Decreases in hsCRP represent reductions in inflammation. LS mean was determined using MMRM model with log (Actual Measurement/Baseline) = log(Baseline) + Baseline Lp(a) stratum (\<275 nmol/L vs. \>=275 nmol/L) + High Risk CV Stratum (yes/no) + Treatment + Time + Treatment\*Time (Type III sum of squares as post-baseline measures. Variance-Covariance structure (Change from Baseline) = Unstructured. Analyses included all participants having non-missing baseline and at least one non-missing post-baseline value of the response variable.

Time frame:
Baseline, Days 60, 180, 240, 360, and 540
Reported as:
Least squares mean · percent change
Percent Change From Baseline in High-sensitivity C-reactive Protein (hsCRP)
percent change16 mg LY381946996 mg LY3819469400 mg LY3819469400 mg LY3819469 + PlaceboPlacebo
Baseline, Day 60-15.4 ± 13.940.1 ± 11.22-1.9 ± 8.00-1.9 ± 8.002.1 ± 11.87
Baseline, Day 18010.6 ± 18.22-6.5 ± 10.5916.2 ± 9.7216.2 ± 9.7210.3 ± 13.17
Baseline, Day 240-3.4 ± 13.02-8.4 ± 8.607.3 ± 9.50-1.2 ± 8.679.1 ± 10.52
Baseline, Day 36043.6 ± 25.2113.5 ± 13.8910.4 ± 12.9032.3 ± 15.3610.8 ± 14.04
Baseline, Day 540-7.7 ± 14.93-1.2 ± 11.190.9 ± 11.1214.1 ± 12.650.1 ± 11.89
Statistical analysis
  • 16 mg LY3819469 vs Placebo · Mixed Models Analysis · p = 0.353 · Ls mean difference (final values): -17.1 · 95% CI -44.3 to 23.3
  • 96 mg LY3819469 vs Placebo · Mixed Models Analysis · p = 0.902 · Ls mean difference (final values): -2.0 · 95% CI -28.7 to 34.7
  • 400 mg LY3819469 vs Placebo · Mixed Models Analysis · p = 0.779 · Ls mean difference (final values): -3.9 · 95% CI -27.4 to 27.1
  • 400 mg LY3819469 + Placebo vs Placebo · Mixed Models Analysis · p = 0.779 · Ls mean difference (final values): -3.9 · 95% CI -27.4 to 27.1
  • 16 mg LY3819469 vs Placebo · Mixed Models Analysis · p = 0.987 · Ls mean difference (final values): 0.3 · 95% CI -32.8 to 49.7
  • 96 mg LY3819469 vs Placebo · Mixed Models Analysis · p = 0.316 · Ls mean difference (final values): -15.2 · 95% CI -38.7 to 17.2
  • 400 mg LY3819469 vs Placebo · Mixed Models Analysis · p = 0.720 · Ls mean difference (final values): 5.4 · 95% CI -20.9 to 40.4
  • 400 mg LY3819469 + Placebo vs Placebo · Mixed Models Analysis · p = 0.720 · Ls mean difference (final values): 5.4 · 95% CI -20.9 to 40.4
  • 16 mg LY3819469 vs Placebo · Mixed Models Analysis · p = 0.461 · Ls mean difference (final values): -11.5 · 95% CI -36.1 to 22.6
  • 96 mg LY3819469 vs Placebo · Mixed Models Analysis · p = 0.194 · Ls mean difference (final values): -16.1 · 95% CI -35.6 to 9.4
  • 400 mg LY3819469 vs Placebo · Mixed Models Analysis · p = 0.898 · Ls mean difference (final values): -1.7 · 95% CI -24.0 to 27.2
  • 400 mg LY3819469 + Placebo vs Placebo · Mixed Models Analysis · p = 0.448 · Ls mean difference (final values): -9.4 · 95% CI -29.9 to 17.0
  • 16 mg LY3819469 vs Placebo · Mixed Models Analysis · p = 0.233 · Ls mean difference (final values): 29.6 · 95% CI -15.4 to 98.4
  • 96 mg LY3819469 vs Placebo · Mixed Models Analysis · p = 0.891 · Ls mean difference (final values): 2.4 · 95% CI -27.6 to 44.9
  • 400 mg LY3819469 vs Placebo · Mixed Models Analysis · p = 0.984 · Ls mean difference (final values): -0.4 · 95% CI -29.0 to 39.9
  • 400 mg LY3819469 + Placebo vs Placebo · Mixed Models Analysis · p = 0.302 · Ls mean difference (final values): 19.4 · 95% CI -14.8 to 67.5
  • 16 mg LY3819469 vs Placebo · Mixed Models Analysis · p = 0.684 · Ls mean difference (final values): -7.9 · 95% CI -37.9 to 36.8
  • 96 mg LY3819469 vs Placebo · Mixed Models Analysis · p = 0.933 · Ls mean difference (final values): -1.4 · 95% CI -28.6 to 36.3
  • 400 mg LY3819469 vs Placebo · Mixed Models Analysis · p = 0.962 · Ls mean difference (final values): 0.8 · 95% CI -26.7 to 38.6
  • 400 mg LY3819469 + Placebo vs Placebo · Mixed Models Analysis · p = 0.422 · Ls mean difference (final values): 13.9 · 95% CI -17.2 to 56.9
SecondaryPharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC[0-inf]) of LY3819469

AUC was computed using the population PK model. Therefore, the concentrations are simulated from time 0 to infinity to estimate AUC for each participant. The timeframe reflects the PK timepoints that were collected to develop the population PK. Although this is a multiple dose study, the plasma PK is very short, so AUC0-180days is equivalent to AUC0-infinity.

Time frame:
Day 1: 0.5 hours, 4-9 hours post-dose; Day 180: 24-36 hours post-dose
Reported as:
Geometric mean · nanogram*hour per milliliter (ng*hr/mL)
Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC[0-inf]) of LY3819469
nanogram*hour per milliliter (ng*hr/mL)16 mg LY381946996 mg LY3819469400 mg LY3819469400 mg LY3819469 + Placebo
Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC[0-inf]) of LY38194691853 ± 3610110 ± 2655242 ± 4246633 ± 13

Adverse events

Collected over Baseline Up to Day 540. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
16 mg LY38194691/36 (2.8%)1/36 (2.8%)14/36 (38.9%)
96 mg LY38194690/74 (0%)9/74 (12.2%)25/74 (33.8%)
400 mg LY38194690/69 (0%)11/69 (15.9%)34/69 (49.3%)
400 mg LY3819469 + Placebo0/72 (0%)8/72 (11.1%)35/72 (48.6%)
Placebo0/69 (0%)6/69 (8.7%)26/69 (37.7%)
Most frequent serious events
Showing 10 of 39
Most frequent serious events
Event16 mg LY381946996 mg LY3819469400 mg LY3819469400 mg LY3819469 + PlaceboPlacebo
Breast cancer femaleNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/91/350/350/270/32
Cardiac failureCardiac disorders1/360/740/690/720/69
Cardiac deathGeneral disorders1/360/740/690/720/69
HyponatraemiaMetabolism and nutrition disorders1/360/740/690/720/69
Atrial fibrillationCardiac disorders0/360/740/690/721/69
CellulitisInfections and infestations0/361/741/690/720/69
Complicated appendicitisInfections and infestations0/360/741/690/720/69
DiverticulitisInfections and infestations0/360/741/690/720/69
Pilonidal diseaseInfections and infestations0/360/741/690/720/69
SepsisInfections and infestations0/360/741/690/720/69
Most frequent other events
Showing 10 of 18
Most frequent other events
Event16 mg LY381946996 mg LY3819469400 mg LY3819469400 mg LY3819469 + PlaceboPlacebo
NasopharyngitisInfections and infestations2/366/745/6910/726/69
Injection site reactionGeneral disorders0/366/748/696/721/69
InfluenzaInfections and infestations4/367/742/694/722/69
Ovarian cystReproductive system and breast disorders1/90/350/350/270/32
Covid-19Infections and infestations2/361/745/694/727/69
Upper respiratory tract infectionInfections and infestations0/365/743/696/720/69
ArthralgiaMusculoskeletal and connective tissue disorders1/362/743/696/722/69
DiarrhoeaGastrointestinal disorders0/360/744/692/723/69
Urinary tract infectionInfections and infestations1/362/744/692/723/69
Alanine aminotransferase increasedInvestigations0/360/744/690/720/69

Baseline characteristics

All randomized participants.

Age, Continuous
Age, Continuous(years)16 mg LY381946996 mg LY3819469400 mg LY3819469400 mg LY3819469 + PlaceboPlaceboTotal
Mean62.6 ± 10.5563.8 ± 9.961.4 ± 10.9362.2 ± 9.6563.5 ± 8.4262.7 ± 9.84
Sex: Female, Male
Sex: Female, Male(Participants)16 mg LY381946996 mg LY3819469400 mg LY3819469400 mg LY3819469 + PlaceboPlaceboTotal
Female935352732138
Male2739344537182
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)16 mg LY381946996 mg LY3819469400 mg LY3819469400 mg LY3819469 + PlaceboPlaceboTotal
Hispanic or Latino781017244
Not Hispanic or Latino2866595567275
Unknown or Not Reported100001
Race (NIH/OMB)
Race (NIH/OMB)(Participants)16 mg LY381946996 mg LY3819469400 mg LY3819469400 mg LY3819469 + PlaceboPlaceboTotal
American Indian or Alaska Native201205
Asian3131381047
Native Hawaiian or Other Pacific Islander000000
Black or African American122207
White3058536059260
More than one race010001
Unknown or Not Reported000000
Region of Enrollment
Region of Enrollment(Participants)16 mg LY381946996 mg LY3819469400 mg LY3819469400 mg LY3819469 + PlaceboPlaceboTotal
Argentina5656224
Netherlands21197736
Romania3324113
United States81719192487
China0313310
Japan310115534
Denmark44541229
Mexico202408
Germany512861041
Spain48714538
Lipoprotein(a) [Lp(a)] level
Lipoprotein(a) [Lp(a)] level(Nanomole/Liter (nmol/L))16 mg LY381946996 mg LY3819469400 mg LY3819469400 mg LY3819469 + PlaceboPlaceboTotal
Mean267.63 ± 81.80278.86 ± 79.53276.66 ± 100.68279.98 ± 93.50266.62 ± 91.31274.74 ± 89.98
08

Study locations

80 sites
  • Care Access - 801 South Power Road, Mesa
    Mesa, Arizona 85206, United States
  • Care Access - South Pasadena
    Pasadena, California 91105, United States
  • Care Access - Santa Clarita
    Santa Clarita, California 91321, United States
  • Care Access - Spring Hill
    Spring Hill, Florida 34609, United States
  • Care Access - Pebble Beach Boulevard, Tampa
    Sun City, Florida 33573, United States
  • Care Access - Tamarac
    Tamarac, Florida 33321, United States
  • Care Access - Tampa
    Tampa, Florida 33625, United States
  • Care Access - Lake Charles
    Lake Charles, Louisiana 70601, United States
  • Care Access - Baltimore
    Baltimore, Maryland 21213, United States
  • Care Access - Dorchester
    Dorchester, Massachusetts 02124, United States
  • Aventiv Research Inc
    Columbus, Ohio 43213, United States
  • Care Access - Lima
    Lima, Ohio 45805, United States
  • Capital Area Research, LLC
    Camp Hill, Pennsylvania 17011, United States
  • Lancaster General Hospital
    Lancaster, Pennsylvania 17602, United States
  • Cardiology Consultants of Philadelphia Yardley
    Yardley, Pennsylvania 19067, United States
  • Care Access - Rapid City
    Rapid City, South Dakota 57701, United States
  • Care Access - Georgetown
    Georgetown, Texas 78633, United States
  • Care Access - Katy
    Katy, Texas 77450, United States
  • Virginia Heart
    Falls Church, Virginia 22042, United States
  • Centro de Investigaciones Metabólicas (CINME)
    Ciudad Autónoma de Buenos Aire, Buenos Air C1027AAP, Argentina
  • Glenny Corp. S.A.
    Buenos Aires, Ciudad Aut C1430CKE, Argentina
  • Mautalen Salud e Investigación
    Buenos Aires, Ciudad Autónoma De Buenos Aires C1128AAF, Argentina
  • Investigaciones Medicas Imoba Srl
    Balvanera, Ciudad Autónoma De Buenos Aire C1056ABH, Argentina
  • CIPREC
    Buenos Aires, Ciudad Autónoma De Buenos Aire C1061AAS, Argentina
  • Centro Modelo de Cardiología
    San Miguel de Tucuman, Tucumán 4000, Argentina
  • Investigaciones Clínicas Tucumán
    San Miguel de Tucuman, Tucumán 4000, Argentina
  • CEMEDIC
    Buenos Aires, 1407, Argentina
  • Hospital San Roque
    Córdoba, 5000, Argentina
  • Centro Cardiovascular Salta
    Salta, 4406, Argentina
  • Centro de Investigaciones Clinicas del Litoral
    Santa Fe, 3000, Argentina
  • Third People's Hospital of Hainan Province
    Sanya, Hainan 572000, China
  • The Second Affiliated Hospital of Nanjing Medical University
    Nanjing, Jiangsu 210011, China
  • The Third Hospital of Nanchang
    Nanchang, Jiangxi 330009, China
  • The First Affiliated Hospital of Xi'an Jiaotong University
    Xi'an, Shaanxi 710061, China
  • Sanos Clinic
    Herlev, Hovedstaden 2730, Denmark
  • Sanos Clinic - Nordjylland
    Gandrup, Nordjylland 9362, Denmark
  • Sanos Clinic - Syddanmark
    Vejle, Syddanmark 7100, Denmark
  • Medizinisches Versorgungszentrum am Bahnhof Spandau
    Spandau, Berlin 13597, Germany
  • Kardiologische Praxis Dr. med. univ. Wolfgang Jungmair
    Bad Homburg, Hessen 61348, Germany
  • Cardioangiologisches Centrum Bethanien
    Frankfurt, Hessen 60389, Germany
  • Klinikum Bielefeld Mitte
    Bielefeld, Nordrhein-Westfalen 33604, Germany
  • SMO.MD GmbH
    Magdeburg, Sachsen-Anhalt 39120, Germany
  • Kardiologische Praxen im Spreebogen
    Berlin, 10559, Germany
  • Cardiologicum Hamburg
    Hamburg, 22041, Germany
  • Diabeteszentrum Hamburg West
    Hamburg, 22607, Germany
  • Sapporo Medical University Hospital
    Sapporo, Hokkaido 060-8543, Japan
  • Hyogo Medical University Hospital
    Nishinomiya, Hyogo 663-8501, Japan
  • Kitasato University Hospital
    Sagamihara, Kanagawa 252-0375, Japan
  • Rinku General Medical Center
    Izumisano, Osaka 598-8577, Japan
  • Tokyo-Eki Center-building Clinic
    Chuo-ku, Tokyo 103-0027, Japan
  • Clinical Research Hospital Tokyo
    Shinjuku-ku, Tokyo 160-0004, Japan
  • Heishinkai Medical Group ToCROM Clinic
    Shinjuku-ku, Tokyo 160-0008, Japan
  • Miyazaki Medical Association Hospital
    Miyazaki, 880-2102, Japan
  • AMC Nishiumeda Clinic
    Osaka, 530-0001, Japan
  • Centro de Investigacion Cardiovascular y Metabólica
    Tijuana, Baja California 22500, Mexico
  • Virgen Cardiovascular Research SC
    Guadalajara, Jalisco 44670, Mexico
  • Centro Para El Desarrollo de La Medicina Y de Asistencia Medica Especializada S.C.
    Culiacán, Sinaloa 80230, Mexico
  • Fundación Cardiovascular de Aguascalientes A.C.
    Aguascalientes, 20230, Mexico
  • Centro de Estudios Clínicos de Querétaro (CECLIQ)
    Querétaro, 76000, Mexico
  • Amphia Ziekenhuis, locatie Breda Molengracht
    Breda, Noord-Brabant 4818 CK, Netherlands
  • Medisch Spectrum Twente
    Enschede, Overijssel 7512 KZ, Netherlands
  • Saxenburgh Medisch Centrum
    Hardenberg, Overijssel 7772 SE, Netherlands
  • Groene Hart Ziekenhuis
    Gouda, Zuid-Holland 2803HH, Netherlands
  • Reinier de Graaf Ziekenhuis, locatie Delft
    Delft, Zuid-Holla 2625 AD, Netherlands
  • Antonius Ziekenhuis, locatie D&A Research and Genetics
    Sneek, 8601 ZR, Netherlands
  • Sal Med Srl
    Pitești, Argeș 110437, Romania
  • C.M.D.T.A. Neomed
    Brasov, Brașov 500283, Romania
  • Hightech Medical Services SRL-Centrul pentru Studiul Metabolismului
    Bucharest, București 011053, Romania
  • Centrul Medical Endocrinologie si Diabet Dr. Paveliu
    Bucharest, București 50538, Romania
  • Private Practice - Dr. Mercea Corina Delia
    Baia Mare, Maramureș 430123, Romania
  • Cardiomed
    Târgu Mureș, Mureș 540124, Romania
  • Private Practice - Dr. Cristian Podoleanu
    Târgu-Mureș, Mureș 540143, Romania
  • Centrul Medical Medicalis
    Timisoara, Timiș 300462, Romania
  • Cardiomed Iași
    Iași, 700687, Romania
  • Hospital Universitario Reina Sofia
    Cordoba, Andalucía 14004, Spain
  • Hospital Germans Trias i Pujol
    Badalona, Barcelona [Barcelona] 08916, Spain
  • Hospital Universitari de Bellvitge
    L'Hospitalet de Llobregat, Catalunya [Cataluña] 08907, Spain
  • Hospital Unviersitario Virgen Nieves
    Granada, 18014, Spain
  • Hospital Universitario Virgen Del Rocio
    Sevilla, 41013, Spain
  • Hospital Universitario Miguel Servet
    Zaragoza, 50009, Spain
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2022 to primary completion in Oct 2023, 12 months.

Results were first posted in May 2025, 1 year 7 months after primary completion. A results delay was requested in Apr 2024.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 3, 2022
First posted
Oct 4, 2022
StartActual
Oct 20, 2022
Primary completionActual
Oct 23, 2023
CompletionActual
Oct 17, 2024
Results delay requested
Apr 4, 2024
Results first posted
May 28, 2025
Last update
May 28, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 28, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05565742
Responsible party
Sponsor
First posted
Oct 4, 2022
Start date
Oct 20, 2022
Primary completion
Oct 23, 2023
Completion
Oct 17, 2024
Results posted
May 28, 2025
Last update
May 28, 2025

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lepodisiran

Start the discussion